4.89
-0.15 (-2.98%)
| Penutupan Terdahulu | 5.04 |
| Buka | 5.05 |
| Jumlah Dagangan | 4,195,832 |
| Purata Dagangan (3B) | 4,343,034 |
| Modal Pasaran | 1,700,183,680 |
| Harga / Jualan (P/S) | 24.16 |
| Harga / Buku (P/B) | 5.06 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 4 May 2026 |
| Margin Operasi (TTM) | -1,913.23% |
| EPS Cair (TTM) | -2.20 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 2.72% |
| Nisbah Semasa (MRQ) | 9.01 |
| Aliran Tunai Operasi (OCF TTM) | -157.34 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -64.76 M |
| Pulangan Atas Aset (ROA TTM) | -23.33% |
| Pulangan Atas Ekuiti (ROE TTM) | -119.66% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Nuvation Bio Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -3.5 |
| Purata | -0.80 |
|
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 19.14% |
| % Dimiliki oleh Institusi | 62.26% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Decheng Capital Llc | 31 Dec 2025 | 25,954,439 |
| Omega Fund Management, Llc | 31 Dec 2025 | 8,081,089 |
| Laurion Capital Management Lp | 31 Dec 2025 | 7,852,638 |
| Tang Capital Management Llc | 31 Dec 2025 | 3,857,457 |
| Redmile Group, Llc | 31 Dec 2025 | 3,163,256 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 13.00 (RBC Capital, 165.85%) | Beli |
| Median | 11.00 (124.95%) | |
| Rendah | 7.00 (UBS, 43.15%) | Pegang |
| Purata | 10.33 (111.25%) | |
| Jumlah | 2 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 4.81 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| RBC Capital | 03 Mar 2026 | 13.00 (165.85%) | Beli | 4.36 |
| UBS | 03 Mar 2026 | 7.00 (43.15%) | Pegang | 4.36 |
| Wedbush | 10 Feb 2026 | 11.00 (124.95%) | Beli | 5.71 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| LIU DONGFANG | - | 5.08 | -50,000 | -254,000 |
| WENTWORTH KERRY | - | 5.08 | -36,750 | -186,690 |
| Jumlah Keseluruhan Kuantiti Bersih | -86,750 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -440,690 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 5.08 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| LIU DONGFANG | Pegawai | 17 Apr 2026 | Jual automatik (-) | 50,000 | 5.08 | 254,000 |
| LIU DONGFANG | Pegawai | 17 Apr 2026 | Pelaksanaan pilihan | 50,000 | - | - |
| WENTWORTH KERRY | Pegawai | 17 Apr 2026 | Jual automatik (-) | 36,750 | 5.08 | 186,690 |
| WENTWORTH KERRY | Pegawai | 17 Apr 2026 | Pelaksanaan pilihan | 36,750 | - | - |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |